PTGX · Protagonist Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.25B |
| P/E | 111.61 |
| Float | 62.52M |
| Beta | 1.18 |
| Volatility | 29.5% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 72 |
| Price | 144.25 |
| Change | +0.87% |
| Prev Close | 143.00 |
| Open | 143.09 |
| Day Low | 140.44 |
| Day High | 144.58 |
| Avg Vol | 1 |
| Avg $ Vol | $98.70M |
| 52W High | 160.81 |
| 52W Low | 58.91 |
| 52W Pos | 83.7% |
| From High | −10.30% |
| From Low | +144.87% |
| Max DD 1Y | −16.38% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −2.03% |
| SMA 50 | +0.43% |
| SMA 200 | +32.73% |
| RSI (14) | 45.2 |
| Vol 30D | 28.4% |
| Vol 90D | 43.3% |
| 1Y Range | 59–161 |
| Daily bars | 516 |
| Perf Week | −3.50% |
| Perf Month | −7.71% |
| Perf Quarter | +26.71% |
| Perf Half Y | +40.64% |
| Perf Year | +141.47% |
| Perf YTD | +65.46% |
| Prev Day | +0.87% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 12.71 |
| Int Cover | -376.8× |
| FCF Margin | 84.8% |
| Rev Growth | +3749.2% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 17 / 35 |
Clavix risk grade
regraded every trading dayPTGX grades B, 72 of 100. Steadiest on News Sentiment (70), most exposed on Price Stability (56, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 17 of 35 in Biotechnology by Clavix score.
How rough the ride is
| PTGX | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.18 | 0.51 |
| Volatilityannualized | 29.5% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −16.4% | — |
| Typical daily movemedian absolute daily change | 1.63% | — |
| Days beyond ±3%of the last 252 sessions | 5823% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| PTGX | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.18 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| PTGX | |
|---|---|
| 1 week | −3.5% |
| 1 month | −7.7% |
| Year to date | +65.5% |
| 1 year | +141.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| PTGX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 29since 27 Jun |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 2 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| PTGX | |
|---|---|
| Revenue growthyear over year | +3749.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article discusses competition in the polycythemia vera treatment market. It notes that Protagonist Therapeutics (PTGX) and partner Takeda recently won FDA approval for their drug Mimrylo, while competitors Disc Medicine and Silence Therapeutics are now advancing their own next-generation therapies to catch up.
Protagonist Therapeutics CEO Dinesh Ph Patel sold 7,278 shares of company stock on September 10th at an average price of $144.10, totaling about $1.05 million. After the sale, he directly owned 522,968 shares worth roughly $75.4 million.
The FDA approved Protagonist's drug MIMRYLO for treating excess red blood cell production in adults with a blood disorder called polycythemia vera, which triggered $275 million in payments to the company: a $200 million opt-out fee (paid when a partner chose to step away from co-commercializing) plus a $75 million approval milestone. The article questions whether collecting ongoing royalty payments would have been a better deal than these upfront lump sums.
The FDA approved MIMRYLO (rusfertide) for adults with polycythemia vera, a rare blood cancer in which the body produces too many red blood cells. The approval also activates milestone payments owed to PTGX by its partner Takeda.
The FDA approved Protagonist Therapeutics' drug MIMRYLO (rusfertide) for adults with polycythemia vera, a rare blood cancer marked by the body making too many red blood cells. MIMRYLO is the first approved treatment that works by mimicking a natural hormone (hepcidin) which controls iron levels and red blood cell production. The approval triggers milestone payments to Protagonist from its partner Takeda, tied to clinical and commercial progress.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $9.39B | — | 1.33 | Compare |
| CYTK | Cytokinetics Inc | B | $9.56B | — | 0.40 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.71B | 19.72 | 1.90 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.97B | 41.27 | 0.56 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.47B | 80.58 | 0.39 | Compare |
| TWST | Twist Bioscience Corp | D+ | $10.99B | — | 2.23 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.39B | — | 0.41 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.